Make Medicine in America Again Act

Bill 117 HR 7166, also known as the Make Medicine in America Again Act, is a piece of legislation introduced in the US Congress. The main goal of this bill is to promote the manufacturing of pharmaceuticals and medical devices within the United States.

The bill includes provisions that aim to incentivize pharmaceutical companies to bring their manufacturing operations back to the US. This is seen as a way to reduce reliance on foreign countries for essential medications and medical supplies, especially in times of crisis such as the COVID-19 pandemic.

Additionally, the Make Medicine in America Again Act includes measures to streamline the regulatory process for drug and medical device manufacturing in the US. This is intended to make it easier for companies to produce these products domestically and ensure that they meet high safety and quality standards. Overall, supporters of the bill argue that increasing domestic manufacturing of pharmaceuticals and medical devices will strengthen national security, create jobs, and reduce the risk of supply chain disruptions. Critics, however, raise concerns about potential cost implications and the impact on global trade relationships. As of now, the Make Medicine in America Again Act is still in the early stages of the legislative process and has not yet been passed into law. It will likely undergo further debate and revisions before potentially being enacted.